[go: up one dir, main page]

DE68914244D1 - Monoklonaler Antikörper. - Google Patents

Monoklonaler Antikörper.

Info

Publication number
DE68914244D1
DE68914244D1 DE89119648T DE68914244T DE68914244D1 DE 68914244 D1 DE68914244 D1 DE 68914244D1 DE 89119648 T DE89119648 T DE 89119648T DE 68914244 T DE68914244 T DE 68914244T DE 68914244 D1 DE68914244 D1 DE 68914244D1
Authority
DE
Germany
Prior art keywords
monoclonal antibody
monoclonal
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89119648T
Other languages
English (en)
Other versions
DE68914244T2 (de
Inventor
Yasukazu Ohmoto
Tsutomu Nishida
Keiko Mizuno
Satoru Nakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of DE68914244D1 publication Critical patent/DE68914244D1/de
Application granted granted Critical
Publication of DE68914244T2 publication Critical patent/DE68914244T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE1989614244 1988-10-24 1989-10-23 Monoklonaler Antikörper. Expired - Fee Related DE68914244T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26789788 1988-10-24

Publications (2)

Publication Number Publication Date
DE68914244D1 true DE68914244D1 (de) 1994-05-05
DE68914244T2 DE68914244T2 (de) 1994-10-27

Family

ID=17451140

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1989614244 Expired - Fee Related DE68914244T2 (de) 1988-10-24 1989-10-23 Monoklonaler Antikörper.

Country Status (2)

Country Link
EP (1) EP0366043B1 (de)
DE (1) DE68914244T2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
AU640400B2 (en) * 1989-08-07 1993-08-26 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6258562B1 (en) 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
MX2007014440A (es) 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
EP2007426A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
NZ621174A (en) 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (de) 2012-09-02 2015-07-08 AbbVie Inc. Verfahren zur steuerung einer proteinheterogenität
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Also Published As

Publication number Publication date
EP0366043B1 (de) 1994-03-30
EP0366043A1 (de) 1990-05-02
DE68914244T2 (de) 1994-10-27

Similar Documents

Publication Publication Date Title
DE68914244D1 (de) Monoklonaler Antikörper.
DK666389A (da) Monoklonalt antistof
DE69018801D1 (de) Chimärischer anti-cae-antikörper.
DE3879452D1 (de) Chimaere antikoerper.
FI925631L (fi) Monoklonala antikroppar
DE3883899D1 (de) Geänderte antikörper.
FI892136L (fi) Rekombinant antikropp.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE3885355D1 (de) Monoklonale Antikörper.
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
DK188185A (da) Monoklonalt antistof
DE3780256D1 (de) Anti-pci-monoklonaler antikoerper.
DE3586808D1 (de) L-thyroxin erkennende monoklonale antikoerper.
NO890116L (no) Monoklonale antistoffer.
DK717888A (da) Monoklonale antistoffer
DK474189A (da) Monoklonalt antistof
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
NO873488D0 (no) Monoklonale antistoffer.
DE69023717D1 (de) Monoklonaler Antikörper.
FI893928A7 (fi) Monoklonala motkroppar.
IT8821702A0 (it) Nuovo anticorpo monoclonale.
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
DE3689183D1 (de) Monoklonaler Antiasialo-GM1-Antikörper.
DK220688D0 (da) Monoklonalt antistof
FI911586A0 (fi) Monoklonala antikroppar mot reseptor-inducerade bindningstaellen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee